(Q24247720)

title

New generation antipsychotics for first episode schizophrenia (English)

0 references

0 references

2

0 references

Stefan Leucht

3

0 references

Christine Rummel-Kluge

4

0 references

author name string

Johannes Hamann

1

0 references

C. Rummel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14584012

26 March 2024

J. Hamann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14584012

26 March 2024

W. Kissling

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14584012

26 March 2024

S. Leucht

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14584012

26 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14584012

26 March 2024

publication date

20 October 2003

0 references

2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14584012

full work available at URL

26 March 2024

https://onlinelibrary.wiley.com/doi/full/10.1002/14651858.CD004410

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

Cochrane Database of Systematic Reviews

26 March 2024

published in

0 references

cites work

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Blood biogenic amines during clozapine treatment of early-onset schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Childhood-onset schizophrenia: an NIMH study in progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Molindone for schizophrenia and severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

A risk-benefit assessment of risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Loxapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Haloperidol versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

The Mount Sinai conference on the pharmacotherapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Compliance with antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

What is an atypical antipsychotic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Sulpiride for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Chlorpromazine versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Haloperidol dose for the acute phase of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

Clinical update on amisulpride in deficit schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004410

7 January 2021

Branded versus generic clozapine: bioavailability comparison and interchangeability issues

26

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

Clozapine in tardive dyskinesia: observations from human and animal model studies

26 March 2024

53

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

Antipsychotic-induced weight gain: a review of the literature

26 March 2024

82

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

Treatment of schizophrenia 1999. The expert consensus guideline series

26 March 2024

112

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

An overview of the mechanism of action of clozapine

26 March 2024

113

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity

26 March 2024

119

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

A rating scale for extrapyramidal side effects

26 March 2024

124

1 reference

https://api.crossref.org/works/10.1002/14651858.CD004410

26 March 2024

Identifiers

0 references